Distribution and Function of EGFR in Human Tissue and the Effect of EGFR Tyrosine Kinase Inhibition

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3639-3650

  Yano, Seiichi ^a   Kondo, Kaoru ^a   Yamaguchi, Motonori ^a   Richmond, Graham ^a   Hutchison, Michael ^a   Wakeling, Alan ^a   Averbuch, Steven ^a   Wadsworth, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

'Iressa'; EGFR; EGFR TKI; Gefitinib; Normal tissue

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ASTHENIA; ATROPHY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; CORNEA EDEMA; CORNEA EPITHELIUM; CORNEA EROSION; CORNEA PERFORATION; CORNEA ULCER; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRY SKIN; FEVER; FLUSHING; FOLLICULITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; KIDNEY PAPILLA NECROSIS; KNOCKOUT MOUSE; LIVER DISEASE; LUNG DISEASE; LUNG FIBROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PRURITUS; RASH; REVIEW; SEBORRHEIC DERMATITIS; SKIN TOXICITY; STOMACH DISTENSION; TREATMENT WITHDRAWAL; TUMOR GROWTH; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MICE; MICE, KNOCKOUT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0345305311     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
2. Wells A: The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal 1: 4-11, 2000.
3. Baselga J: New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1: 12-21, 2000.
4. Lundberg AS and Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer 35: 1886-1894, 1999.
5. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37: S9-15, 2001.
6. Robertson KW, Reeves JR, Lannigan AK, Going JJ, Cooke TG and Stanton PD: Radioimmunohistochemistry of epidermal growth factor receptor in breast cancer. Arch Pathol Lab Med 126: 177-181, 2002.
7. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI and Baselga J: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124, 2002.
8. Klijn JG, Berns PM, Schmitz PI and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 3: 3-17, 1992.
9. Nanney LB, McKanna JA, Stoscheck CM, Carpenter G and King LE: Visualization of epidermal growth factor receptors in human epidermis. J Invest Dermatol 82: 165-169, 1984.
10. Green MR and Couchman JR: Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 85: 239-245, 1985.
11. Whitcomb SS, Eversole LR and Lindemann RA: Immunohistochemical mapping of epidermal growth-factor receptors in normal human oral soft tissue. Arch Oral Biol 38: 823-826, 1993.
12. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M and Buchler MW: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23: 1010-1018, 1999.
13. Calabro A, Orsini B, Renzi D, Papi L, Surrenti E, Amorosi A, Herbst H, Milani S and Surrenti C: Expression of epidermal growth factor, transforming growth factor-alpha and their receptor in the human oesophagus. Histochem J 29: 745-758, 1997.
14. Tarnawski AS and Jones MK: The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 27: S12-S20, 1998.
15. Playford RJ, Hanby AM, Gschmeissner S, Peiffer LP, Wright NA and McGarrity T: The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut 39: 262-266, 1996.
16. Fukusato T, Mori S, Kawamoto T, Taniguchi S and Machinami R: Immunohistochemical and ultrastructural localization of epidermal growth factor receptor in human liver and hepatocellular carcinoma tissues. Acta Pathol Jpn 40: 22-29, 1990.
17. Tomioka T, Toshkov I, Kazakoff K, Andren-Sandberg A, Takahashi T, Buchler M, Friess H, Vaughn R and Pour PM: Cellular and subcellular localization of transforming growth factor-alpha and epidermal growth factor receptor in normal and diseased human and hamster pancreas. Teratog Carcinog Mutagen 15: 231-250, 1995.
18. Zieske JD and Wasson M: Regional variation in distribution of EGF receptor in developing and adult corneal epithelium. J Cell Sci 106: 145-152, 1993.
19. Liu Z, Carvajal M, Carraway CA, Carraway K and Pflugfelder SC: Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia. Cornea 20: 81-85, 2001.
20. Yoneda K: Distribution of proliferating-cell nuclear antigen and epidermal growth factor receptor in intraepithelial squamous cell lesions of human bronchus. Mod Pathol 7: 480-486, 1994.
21. Polosa R, Prosperini G, Leir SH, Holgate ST, Lackie PM and Davies DE: Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20: 914-923, 1999.
22. Strandjord TP, Clark JG, Guralnick DE and Madtes DK: Immunolocalization of transforming growth factor-alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung. Pediatr Res 38: 851-856, 1995.
23. Gompel A, Martin A, Simon P, Schoevaert D, Plu-Bureau G, Hugol D, Audouin J, Leygue E, Truc JB and Poitout P: Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. Breast Cancer Res Treat 38: 227-235, 1996.
24. Stewart CJ, Owens OJ, Richmond JA and McNicol AM: Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 11: 266-272, 1992.
25. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL and Bast RC Jr: Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 76: 381-387, 1990.
26. Kupryjanczyk J: Epidermal growth factor receptor expression in the normal and inflamed cervix uteri: a comparison with estrogen receptor expression. Int J Gynecol Pathol 9: 263-271, 1990.
27. Elson SD, Browne CA and Thorburn GD: Identification of epidermal growth factor-like activity in human male reproductive tissues and fluids. J Clin Endocrinol Metab 58: 589-594, 1984.
28. Iwamura M, di Sant'agnese PA, Wu G, Benning CM, Cockett AT and Gershagen S: Overexpression of human epidermal growth factor receptor and c-erbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 43: 838-843, 1994.
29. Leav I, McNeal JE, Ziar J and Alroy J: The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions. Hum Pathol 29: 668-675, 1998.
30. De Miguel P, Royuela M, Bethencourt R, Ruiz A, Fraile B and Paniagua R: Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11: 722-727, 1999.
31. Yoshioka K, Takemura T, Murakami K, Akano N, Matsubara K, Aya N and Maki S: Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab Invest 63: 189-196, 1990.
32. Chow NH, Liu HS, Yang HB, Chan SH and Su IJ: Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchow Arch 430: 461-466, 1997,
33. Le PT, Lazorick S, Whichard LP, Haynes BF and Singer KH: Regulation of cytokine production in the human thymus: epidermal growth factor and transforming growth factor alpha regulate mRNA levels of interleukin 1 alpha (IL-1 alpha), IL-1 beta, and IL-6 in human thymic epithelial cells at a posttranscriptional level. J Exp Med 174: 1147-1157, 1991.
34. Kramer A, Yang FC, Snodgrass P, Li X, Scammell TE, Davis FC and Weitz CJ: Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 294: 2511-2515, 2001.
35. Chaidarun SS, Eggo MC, Sheppard MC and Stewart PM: Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135: 2012-2021, 1994.
36. Kamio T, Shigematsu K, Sou H, Kawai K and Tsuchiyama H: Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21: 277-282, 1990.
37. Jost M, Kari C and Rodeck U: The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10: 505-510, 2000.
38. Kobayashi T, Hashimoto K, Okumura H, Asada H and Yoshikawa K: Endogenous EGF-family growth factors are necessary for the progression from the G1 to S phase in human keratinocytes. J Invest Dermatol 111: 616-620, 1998.
39. Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, Sudo K, Nakagawa T, Damm D, Yoshikawa K and Taniguchi N: Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 269: 20060-20066, 1994.
40. Vardy DA, Kari C, Lazarus GS, Jensen PJ, Zilberstein A, Plowman GD and Rodeck U: Induction of autocrine epidermal growth factor receptor ligands in human keratinocytes by insulin/insulin-like growth factor-1. J Cell Physiol 163: 257-265, 1995.
41. Barrandon Y and Green H: Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell 50: 1131-1137, 1987.
42. Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR and Todaro GJ: Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science 235: 350-352, 1987.
43. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL and Jensen PJ: EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110: 113-121, 1997.
44. Stromblad S and Andersson G: The coupling between transforming growth factor-alpha and the epidermal growth factor receptor during rat liver regeneration. Exp Cell Res 204: 321-328, 1993.
45. Wilson SE, He YG and Lloyd SA: EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci 33: 1756-1765, 1992.
46. Nakamura Y, Sotozono C and Kinoshita S: The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 72: 511-517, 2001.
47. Zieske JD, Takahashi H, Hutcheon AE and Dalbone AC: Activation of epidermal growth factor receptor during corneal epithelial migration. Invest Ophthalmol Vis Sci 41: 1346-1355, 2000.
48. Coleman S and Daniel CW: Inhibition of mouse mammary ductal morphogenesis and down-regulation of the EGF receptor by epidermal growth factor. Dev Biol 137: 425-433, 1990.
49. Troyer KL and Lee DC: Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 6: 7-21, 2001.
50. Wiesen JF, Young P, Werb Z and Cunha GR: Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126: 335-344, 1999.
51. Gupta C, Chandorkar A and Nguyen AP: Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. Mol Cell Endocrinol 123: 89-95, 1996.
52. Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST and Davies DE: Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 14: 1362-1374, 2000.
53. Harris RC and Daniel TO: Epidermal growth factor binding, stimulation of phosphorylation, and inhibition of gluconeogenesis in rat proximal tubule. J Cell Physiol 139: 383-391, 1989.
54. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z and Derynck R: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376: 337-341, 1995.
55. Threadgill DW, Dlugosz AA, Hansen L, Tennenbaum T, Lichti U, Yee D, LeMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ and Magnuson T: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269: 230-234, 1995.
56. Sibilia M and Wagner EF: Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269: 234-238, 1995.
57. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S and Rowinsky EK: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279, 2001.
58. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A, Feyereislova A and Baselga J: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a, abs 1188, 2002.
59. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J and Kay A: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a, abs 1166, 2002.
60. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H and Rowinsky EK: ZD1839 a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of phase I trial. J Clin Oncol 20: 2240-2250, 2002.
61. Ranson M, Mansoor W and Jayson G: ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther 2: 161-168, 2002.
62. Suzuki H, Aoshiba K, Yokohori N and Nagai A: The effects of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) on bleomycin-induced pulmonary fibrosis in mice. Proceedings of the 4th Tokyo Lung Research Conference 11-2, 2002.
63. Greaves P (Editor): Histopathology of Preclinical Toxicity Studies. Interpretation and Relevance in Drug Safety Evaluation. Amsterdam, Elsevier, 2000 pp 230.
64. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H and Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000.